A Study to Characterize the Outcomes of Olaparib Maintenance Monotherapy in Newly Diagnosed BRCAwt Ovarian Cancer
NCT05775549 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 24
Last updated 2024-09-20
Summary
This study will collect the data from existing patient medical records at US cancer centers. The study will include patients with BRCAwt ovarian cancer who have been prescribed first line (1L) olaparib maintenance treatment.
Conditions
- Advanced Ovarian Cancer
Interventions
- OTHER
-
None (Observational Study)
Not Applicable since observational study
Sponsors & Collaborators
- collaborator INDUSTRY
- lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Max Age
- 130 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-07-10
- Primary Completion
- 2023-10-27
- Completion
- 2023-10-27
Countries
- United States
Study Locations
More Related Trials
-
Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer
NCT06856499 ·Status: RECRUITING ·Phase: PHASE1
-
Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known Homologous Recombination Deficiency
NCT06120972 ·Status: WITHDRAWN ·Phase: PHASE2
-
Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation
NCT02953457 ·Status: COMPLETED ·Phase: PHASE2
-
OSCA - Olaparib Standard of CAre Study
NCT02262273 ·Status: COMPLETED
-
Outcomes of First-line Olaparib Mono-maintenance therapy-a Multicenter, Retrospective Study Using Data From Real-world Clinical Setting
NCT05153603 ·Status: UNKNOWN
-
Olaparib in Patients With Recurrent Ovarian Cancer Wild Type for Germline and Somatic BRCA 1 and 2 Genes: The MITO 31 Translational Study
NCT04091204 ·Status: UNKNOWN ·Phase: PHASE2
-
Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations
NCT02392676 ·Status: WITHDRAWN ·Phase: PHASE3
-
Real-life Data of Olaparib in Relapsed Ovarian Cancers Patients
NCT04152941 ·Status: COMPLETED
-
Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments
NCT02282020 ·Status: COMPLETED ·Phase: PHASE3
-
Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status
NCT02983799 ·Status: COMPLETED ·Phase: PHASE2
-
Fluzopari Combined With Apatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer
NCT05597527 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of Fluzoparib（SHR-3162）in BRCA1/2-mutant Relapsed Ovarian Cancer
NCT03509636 ·Status: COMPLETED ·Phase: PHASE1
-
Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy
NCT05295589 ·Status: WITHDRAWN ·Phase: PHASE2
-
Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian Cancer
NCT01650376 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Olaparib, Durvalumab and UV1 in Relapsed Ovarian Cancer
NCT04742075 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
C-PATROL - Non-interventional Study (NIS) to Collect Clinical and Patient Reported Outcome Data in an Olaparib Treated BRCAm+ PSR Ovarian Cancer Population
NCT02503436 ·Status: COMPLETED
-
A Study of Long-Term Responders on Olaparib
NCT02489058 ·Status: COMPLETED
-
Characterization of Epithelial Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype
NCT05574673 ·Status: RECRUITING
-
Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer
NCT01081951 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer
NCT06063070 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)
NCT03740165 ·Status: COMPLETED ·Phase: PHASE3
-
Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery
NCT03943173 ·Status: ACTIVE_NOT_RECRUITING ·Phase: EARLY_PHASE1
-
Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
NCT03534453 ·Status: COMPLETED ·Phase: PHASE3
-
Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer
NCT02502266 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2/PHASE3
-
An Open Label Study To Investigate the Pharmacokinetics and Pharmacodynamics of Repeat Escalating Doses of the Oral AKT Inhibitor GSK2141795 by 18F FDG PET Analysis in Subjects With Ovarian Cancer
NCT01266954 ·Status: COMPLETED ·Phase: PHASE1